Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.69 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.60 |
| ▸ | NMT2 | O60551 | 1/20 | 0.56 |
| ▸ | NMT1 | P30419 | 1/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15363905 | 1.00 | SLC6A5 (0.69) | SLC6A5NOD1NMT2NMT1PLA2G10 | |
| SCHEMBL30496951 | 1.00 | SLC6A5 (0.69) | SLC6A5NOD1NMT2NMT1PLA2G10 | |
| SCHEMBL29640398 | 1.00 | SLC6A5 (0.69) | SLC6A5NOD1NMT2NMT1PLA2G10 | |
| SCHEMBL30496941 | 1.00 | SLC6A5 (0.69) | SLC6A5NOD1NMT2NMT1PLA2G10 | |
| SCHEMBL5955042 | 0.96 | SLC6A5 (0.64) | SLC6A5NOD1NMT2NMT1PLA2G10 | |
| SCHEMBL29414633 | 0.94 | SLC6A5 (0.62) | SLC6A5NOD1NMT2NMT1PLA2G10 | |
| SCHEMBL29111716 | 0.91 | SLC6A5 (0.77) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL8929340 | 0.91 | SLC6A5 (0.77) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL16976108 | 0.91 | NMT1 (0.58) | SLC6A5NOD1NMT2NMT1PLA2G10 | |
| SCHEMBL10046596 | 0.89 | TLR2 (0.63) | SLC6A5NOD1NMT2NMT1PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116979-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | NISSAN CHEMICAL CORPORATION (JP) | 2024-04-11 | — | — | US | disclosed |
| US-20240067675-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | NISSAN CHEMICAL CORPORATION (JP) | 2024-02-29 | — | — | US | disclosed |
| EP-4265629-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | Nissan Chemical Corporation (JP) | 2023-10-25 | — | — | EP | disclosed |
| CN-116648455-A | Method for preparing lipid peptide | 日产化学株式会社 | 2023-08-25 | — | — | CN | disclosed |
| CN-116615435-A | Method for preparing lipid peptide | 日产化学株式会社 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022138953-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | 日産化学株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022138957-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | 日産化学株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067675-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | VIP, NGLY1, NPPA | SLC6A5 1803/4885NOD1 4121/4885NMT2 819/4885 |
| US-20240116979-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | NPPA, VIP, NGLY1 | SLC6A5 1172/4885NOD1 4139/4885NMT2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.